CYP20A1
gene geneOn this page
Also known as CYP-M
Summary
CYP20A1 (cytochrome P450 family 20 subfamily A member 1, HGNC:20576) is a protein-coding gene on chromosome 2q33.2, encoding Cytochrome P450 20A1 (Q6UW02).
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein lacks one amino acid of the conserved heme binding site. It also lacks the conserved I-helix motif AGX(D,E)T, suggesting that its substrate may carry its own oxygen.
Source: NCBI Gene 57404 — RefSeq curated summary.
At a glance
- GWAS associations: 17
- Clinical variants (ClinVar): 82 total
- MANE Select transcript:
NM_177538
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:20576 |
| Approved symbol | CYP20A1 |
| Name | cytochrome P450 family 20 subfamily A member 1 |
| Location | 2q33.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | CYP-M |
| Ensembl gene | ENSG00000119004 |
| Ensembl biotype | protein_coding |
| Entrez | 57404 |
Gene structure
Transcript identifiers
Ensembl transcripts: 12 — 6 protein_coding, 3 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined
ENST00000356079, ENST00000428265, ENST00000429815, ENST00000431118, ENST00000443941, ENST00000449301, ENST00000461371, ENST00000463131, ENST00000489360, ENST00000875108, ENST00000875109, ENST00000956048
RefSeq mRNA: 13 — MANE Select: NM_177538
NM_001371695, NM_001371696, NM_001371697, NM_001371698, NM_001371699, NM_001371700, NM_001371701, NM_001371702, NM_001371703, NM_001371704, NM_001371705, NM_001371706, NM_177538
CCDS: CCDS2357, CCDS92931
Canonical transcript exons
ENST00000356079 — 13 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000803483 | 203246755 | 203246921 |
| ENSE00001076405 | 203245846 | 203245895 |
| ENSE00001554594 | 203296758 | 203306026 |
| ENSE00001905806 | 203239018 | 203239134 |
| ENSE00003493353 | 203280059 | 203280113 |
| ENSE00003539280 | 203251967 | 203252109 |
| ENSE00003573542 | 203296474 | 203296563 |
| ENSE00003575020 | 203278573 | 203278688 |
| ENSE00003661257 | 203266514 | 203266681 |
| ENSE00003668160 | 203272670 | 203272748 |
| ENSE00003671815 | 203292262 | 203292326 |
| ENSE00003675193 | 203289765 | 203289876 |
| ENSE00003785833 | 203285612 | 203285732 |
Expression profiles
Bgee: expression breadth ubiquitous, 225 present calls, max score 93.36.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.1715 / max 525.3354, expressed in 1816 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 24746 | 9.5434 | 1799 |
| 24747 | 8.8754 | 1771 |
| 24748 | 0.7528 | 434 |
Top tissues by expression
271 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| calcaneal tendon | UBERON:0003701 | 93.36 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 92.04 | gold quality |
| adrenal tissue | UBERON:0018303 | 91.70 | gold quality |
| colonic epithelium | UBERON:0000397 | 88.75 | gold quality |
| monocyte | CL:0000576 | 85.80 | gold quality |
| islet of Langerhans | UBERON:0000006 | 85.52 | gold quality |
| mononuclear cell | CL:0000842 | 85.31 | gold quality |
| leukocyte | CL:0000738 | 85.24 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 84.78 | gold quality |
| tendon | UBERON:0000043 | 83.86 | gold quality |
| body of pancreas | UBERON:0001150 | 83.17 | gold quality |
| pancreas | UBERON:0001264 | 83.02 | gold quality |
| adrenal gland | UBERON:0002369 | 82.82 | gold quality |
| rectum | UBERON:0001052 | 82.74 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 82.55 | gold quality |
| right adrenal gland | UBERON:0001233 | 82.36 | gold quality |
| left adrenal gland | UBERON:0001234 | 82.31 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 81.95 | gold quality |
| popliteal artery | UBERON:0002250 | 81.46 | gold quality |
| tibial artery | UBERON:0007610 | 81.46 | gold quality |
| gall bladder | UBERON:0002110 | 81.42 | gold quality |
| adrenal cortex | UBERON:0001235 | 81.28 | gold quality |
| stromal cell of endometrium | CL:0002255 | 81.06 | gold quality |
| aorta | UBERON:0000947 | 80.87 | gold quality |
| left coronary artery | UBERON:0001626 | 80.82 | gold quality |
| right testis | UBERON:0004534 | 80.80 | gold quality |
| sural nerve | UBERON:0015488 | 80.62 | gold quality |
| thoracic aorta | UBERON:0001515 | 80.26 | gold quality |
| ascending aorta | UBERON:0001496 | 80.20 | gold quality |
| left ovary | UBERON:0002119 | 80.16 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 8.83 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): TCF3
Literature-anchored findings (GeneRIF, showing 2)
- Multiple Alu Exonization in 3’UTR of a Primate-Specific Isoform of CYP20A1 Creates a Potential miRNA Sponge. (PMID:33434274)
- The association study between CYP20A1, CYP4F2, CYP2D6 gene polymorphisms and coronary heart disease risk in the Han population in southern China. (PMID:34302632)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | cyp20a1 | ENSDARG00000006040 |
| mus_musculus | Cyp20a1 | ENSMUSG00000049439 |
| rattus_norvegicus | Cyp20a1 | ENSRNOG00000017631 |
Protein
Protein identifiers
Cytochrome P450 20A1 — Q6UW02 (reviewed: Q6UW02)
All UniProt accessions (5): Q6UW02, C9J8K7, E9PHG5, F2Z3K6, F8WBE2
UniProt curated annotations — full annotation on UniProt →
Subcellular location. Membrane.
Similarity. Belongs to the cytochrome P450 family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q6UW02-1 | 1 | yes |
| Q6UW02-2 | 2 |
RefSeq proteins (13): NP_001358624, NP_001358625, NP_001358626, NP_001358627, NP_001358628, NP_001358629, NP_001358630, NP_001358631, NP_001358632, NP_001358633, NP_001358634, NP_001358635, NP_803882* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001128 | Cyt_P450 | Family |
| IPR002401 | Cyt_P450_E_grp-I | Family |
| IPR036396 | Cyt_P450_sf | Homologous_superfamily |
| IPR052666 | CYP450_20A1-like | Family |
Pfam: PF00067
UniProt features (9 total): sequence conflict 3, sequence variant 2, chain 1, transmembrane region 1, binding site 1, splice variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q6UW02-F1 | 89.00 | 0.64 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Ligand- & substrate-binding residues (1): 409 (axial binding residue)
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 135 (showing top):
GSE45365_NK_CELL_VS_CD8_TCELL_UP, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, CUI_TCF21_TARGETS_2_DN, GOMF_TETRAPYRROLE_BINDING, GOMF_IRON_ION_BINDING, GOMF_MONOOXYGENASE_ACTIVITY, CCACACA_MIR147, KASLER_HDAC7_TARGETS_1_UP, PTEN_DN.V2_DN, GSE13522_CTRL_VS_T_CRUZI_Y_STRAIN_INF_SKIN_IFNG_KO_UP, GSE14415_INDUCED_TREG_VS_FAILED_INDUCED_TREG_UP, GSE14415_ACT_VS_CTRL_NATURAL_TREG_UP, GSE14386_UNTREATED_VS_IFNA_TREATED_ACT_PBMC_MS_PATIENT_DN, GSE13547_2H_VS_12_H_ANTI_IGM_STIM_BCELL_DN
GO Biological Process (0):
GO Molecular Function (7): monooxygenase activity (GO:0004497), iron ion binding (GO:0005506), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705), heme binding (GO:0020037), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), metal ion binding (GO:0046872)
GO Cellular Component (1): membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| oxidoreductase activity | 2 |
| transition metal ion binding | 1 |
| tetrapyrrole binding | 1 |
| binding | 1 |
| catalytic activity | 1 |
| cation binding | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
1512 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CYP20A1 | ICA1L | Q8NDH6 | 544 |
| CYP20A1 | GK5 | Q6ZS86 | 542 |
| CYP20A1 | CYP39A1 | Q9NYL5 | 532 |
| CYP20A1 | C17orf75 | Q9HAS0 | 521 |
| CYP20A1 | DCAF10 | Q5QP82 | 514 |
| CYP20A1 | ZNF429 | Q86V71 | 497 |
| CYP20A1 | CYP7A1 | P22680 | 490 |
| CYP20A1 | ZNF850 | A8MQ14 | 461 |
| CYP20A1 | PPIH | O43447 | 453 |
| CYP20A1 | ZNF714 | Q96N38 | 449 |
| CYP20A1 | CYB5D2 | Q8WUJ1 | 444 |
| CYP20A1 | CIAO1 | O76071 | 443 |
| CYP20A1 | CACNG8 | Q8WXS5 | 438 |
| CYP20A1 | FKBP14 | Q9NWM8 | 437 |
| CYP20A1 | HSD3B7 | Q9H2F3 | 437 |
IntAct
18 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| VSIG1 | TTI1 | psi-mi:“MI:0914”(association) | 0.640 |
| CYP20A1 | PIEZO1 | psi-mi:“MI:0915”(physical association) | 0.590 |
| BTNL3 | FAM171A2 | psi-mi:“MI:0914”(association) | 0.530 |
| VSIG1 | TNPO2 | psi-mi:“MI:0914”(association) | 0.530 |
| Rrbp1 | PIPSL | psi-mi:“MI:0914”(association) | 0.350 |
| COPE | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| TMED10 | PGRMC1 | psi-mi:“MI:0914”(association) | 0.350 |
| SLC11A2 | GPR89A | psi-mi:“MI:0914”(association) | 0.350 |
| SLC16A6 | RER1 | psi-mi:“MI:0914”(association) | 0.350 |
| SLC17A3 | ADCY3 | psi-mi:“MI:0914”(association) | 0.350 |
| SLC44A1 | UPK3BL1 | psi-mi:“MI:0914”(association) | 0.350 |
| SLC7A8 | SPTLC1 | psi-mi:“MI:0914”(association) | 0.350 |
| CFTR | UBA6 | psi-mi:“MI:2364”(proximity) | 0.270 |
BioGRID (31): CYP20A1 (Synthetic Growth Defect), CYP20A1 (Affinity Capture-MS), PIEZO1 (Affinity Capture-MS), CYP20A1 (Affinity Capture-MS), CYP20A1 (Affinity Capture-MS), CYP20A1 (Affinity Capture-MS), CYP20A1 (Affinity Capture-MS), CYP20A1 (Affinity Capture-MS), CYP20A1 (Affinity Capture-RNA), CYP20A1 (Affinity Capture-MS), CYP20A1 (Affinity Capture-MS), CYP20A1 (Affinity Capture-MS), PIEZO1 (Affinity Capture-MS), CYP20A1 (Affinity Capture-MS), CYP20A1 (Affinity Capture-MS)
ESM2 similar proteins: A0A1V6PBE7, A0A5B8ND22, A0A9Y1LLN2, A8WGA0, E1BHJ4, F1RE08, G3V7X8, I1GQE7, M1W080, O02766, O23051, O46491, O75881, O88962, O93323, P0DOX0, P0DXH8, P18125, P22680, P46634, P48416, P51542, P79739, Q07973, Q08D50, Q09128, Q09660, Q4G0S4, Q50EK5, Q5E980, Q60991, Q62969, Q63688, Q64441, Q64505, Q6EIG3, Q6JD68, Q6P7D4, Q6UW02, Q7YRB2
Diamond homologs: A0A159AKG3, A0A1Z3GBS4, A0A218NGS0, A8NCK6, B5UAQ8, C8VJR0, E9Q5K4, F1B282, H2DH19, H2DH24, H2KYS3, O04773, O18809, O18963, O18993, O46515, O65012, O70537, O77809, O77810, P04800, P05181, P05182, P05183, P0DO35, P0DO40, P0DO41, P0DO42, P11509, P20853, P24454, P24462, P24470, P33266, P37123, P51538, P79102, Q05555, Q05556, Q16696
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
82 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 53 |
| Likely benign | 2 |
| Benign | 2 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2159 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 2:203245844:A:G | acceptor_gain | 1.0000 |
| 2:203245891:GAAAA:G | donor_gain | 1.0000 |
| 2:203245894:AA:A | donor_gain | 1.0000 |
| 2:203245896:G:GG | donor_gain | 1.0000 |
| 2:203246922:G:GG | donor_gain | 1.0000 |
| 2:203251965:A:AG | acceptor_gain | 1.0000 |
| 2:203251965:AGC:A | acceptor_gain | 1.0000 |
| 2:203251966:G:GA | acceptor_gain | 1.0000 |
| 2:203251966:GC:G | acceptor_gain | 1.0000 |
| 2:203251966:GCG:G | acceptor_gain | 1.0000 |
| 2:203252107:AAGG:A | donor_loss | 1.0000 |
| 2:203252108:AGG:A | donor_loss | 1.0000 |
| 2:203252110:G:C | donor_loss | 1.0000 |
| 2:203252111:T:A | donor_loss | 1.0000 |
| 2:203266512:A:AG | acceptor_gain | 1.0000 |
| 2:203266513:G:GC | acceptor_gain | 1.0000 |
| 2:203266513:GC:G | acceptor_gain | 1.0000 |
| 2:203266513:GCT:G | acceptor_gain | 1.0000 |
| 2:203266513:GCTT:G | acceptor_gain | 1.0000 |
| 2:203266513:GCTTT:G | acceptor_gain | 1.0000 |
| 2:203266649:G:GT | donor_gain | 1.0000 |
| 2:203266677:GCACA:G | donor_gain | 1.0000 |
| 2:203266678:CACA:C | donor_gain | 1.0000 |
| 2:203266679:ACA:A | donor_gain | 1.0000 |
| 2:203266679:ACAGT:A | donor_loss | 1.0000 |
| 2:203266680:CA:C | donor_gain | 1.0000 |
| 2:203266681:AGT:A | donor_loss | 1.0000 |
| 2:203266682:G:GG | donor_gain | 1.0000 |
| 2:203266682:GTAA:G | donor_loss | 1.0000 |
| 2:203266683:T:A | donor_loss | 1.0000 |
AlphaMissense
3040 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 2:203246870:A:C | S80R | 0.998 |
| 2:203246872:T:A | S80R | 0.998 |
| 2:203246872:T:G | S80R | 0.998 |
| 2:203239085:C:A | A8D | 0.989 |
| 2:203246868:T:A | V79D | 0.989 |
| 2:203266538:T:A | W153R | 0.989 |
| 2:203266538:T:C | W153R | 0.989 |
| 2:203246760:G:A | G43D | 0.988 |
| 2:203246764:T:A | N44K | 0.988 |
| 2:203246764:T:G | N44K | 0.988 |
| 2:203289797:G:C | R335P | 0.988 |
| 2:203296475:T:C | F384L | 0.983 |
| 2:203296477:T:A | F384L | 0.983 |
| 2:203296477:T:G | F384L | 0.983 |
| 2:203246760:G:T | G43V | 0.981 |
| 2:203246805:T:C | L58P | 0.979 |
| 2:203292269:T:A | V364D | 0.976 |
| 2:203246801:T:C | F57L | 0.968 |
| 2:203246803:C:A | F57L | 0.968 |
| 2:203246803:C:G | F57L | 0.968 |
| 2:203246843:T:C | F71L | 0.967 |
| 2:203246845:C:A | F71L | 0.967 |
| 2:203246845:C:G | F71L | 0.967 |
| 2:203289788:A:T | E332V | 0.967 |
| 2:203246759:G:C | G43R | 0.965 |
| 2:203239115:C:A | A18D | 0.964 |
| 2:203296490:T:C | F389L | 0.962 |
| 2:203296492:T:A | F389L | 0.962 |
| 2:203296492:T:G | F389L | 0.962 |
| 2:203296532:T:C | F403L | 0.959 |
dbSNP variants (sampled 300 via entrez): RS1000065184 (2:203297639 C>A,G,T), RS1000080031 (2:203274172 A>C), RS1000088013 (2:203281945 T>A), RS1000101987 (2:203261973 C>A,G), RS1000352902 (2:203268987 C>T), RS1000376085 (2:203286184 G>A), RS1000378391 (2:203293428 G>A,T), RS1000399951 (2:203286221 C>T), RS1000447371 (2:203293336 C>T), RS1000493735 (2:203252884 C>T), RS1000499607 (2:203292898 G>A), RS1000597383 (2:203297804 C>A), RS1000608156 (2:203255605 C>G,T), RS1000663071 (2:203239278 G>A,C,T), RS1000684495 (2:203280303 C>G,T)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
17 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000839_5 | Height | 2.000000e-06 |
| GCST007094_143 | Diastolic blood pressure | 7.000000e-06 |
| GCST007096_201 | Pulse pressure | 3.000000e-09 |
| GCST007097_26 | Pulse pressure | 8.000000e-06 |
| GCST008876_22 | Non-lobar intracerebral hemorrhage (MTAG) | 1.000000e-06 |
| GCST010101_5 | White matter hyperintensities | 4.000000e-13 |
| GCST010102_1 | White matter integrity (fractional anisotropy) | 7.000000e-08 |
| GCST010698_18 | Subcortical volume (min-P) | 1.000000e-08 |
| GCST010699_69 | Brain morphology (min-P) | 9.000000e-20 |
| GCST010700_6 | Cortical thickness (MOSTest) | 2.000000e-14 |
| GCST010701_36 | Cortical surface area (MOSTest) | 2.000000e-24 |
| GCST010702_146 | Subcortical volume (MOSTest) | 2.000000e-13 |
| GCST010703_42 | Brain morphology (MOSTest) | 1.000000e-08 |
| GCST010726_18 | Periventricular white matter hyperintensities | 7.000000e-08 |
| GCST90000025_865 | Appendicular lean mass | 7.000000e-15 |
| GCST90011900_136 | Serum alkaline phosphatase levels | 5.000000e-24 |
| GCST90013406_59 | Liver enzyme levels (alkaline phosphatase) | 7.000000e-30 |
EFO canonical traits (9, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0006336 | diastolic blood pressure |
| EFO:0005763 | pulse pressure measurement |
| EFO:0010178 | non-lobar intracerebral hemorrhage |
| EFO:0005665 | white matter hyperintensity measurement |
| EFO:0004641 | white matter integrity |
| EFO:0004346 | neuroimaging measurement |
| EFO:0004840 | cortical thickness |
| EFO:0004980 | appendicular lean mass |
| EFO:0004533 | alkaline phosphatase measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
GtoPdb / IUPHAR curated pharmacology
(IUPHAR/BPS Guide to Pharmacology — expert-curated)
Target class: enzyme — CYP11, CYP17, CYP19, CYP20 and CYP21 families
CTD chemical–gene interactions
29 total (human), top 29 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | increases abundance, increases expression | 3 |
| Valproic Acid | affects expression, decreases expression | 2 |
| Cyclosporine | increases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| bisphenol A | increases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | increases expression | 1 |
| butyraldehyde | decreases expression | 1 |
| manganese chloride | increases abundance, increases expression | 1 |
| perfluorooctane sulfonic acid | increases expression | 1 |
| fipronil | affects cotreatment, decreases expression | 1 |
| 2-palmitoylglycerol | increases expression | 1 |
| Decitabine | affects expression | 1 |
| Sunitinib | increases expression | 1 |
| Acetaminophen | increases expression | 1 |
| Arsenic | increases abundance, increases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Cadmium | increases abundance, increases expression | 1 |
| Cisplatin | affects expression | 1 |
| DEET | affects cotreatment, decreases expression | 1 |
| Diethylstilbestrol | decreases expression | 1 |
| Endosulfan | increases expression | 1 |
| Gallic Acid | decreases expression | 1 |
| Manganese | increases abundance, increases expression | 1 |
| Methyl Methanesulfonate | increases expression | 1 |
| Silicon Dioxide | decreases expression | 1 |
| Smoke | decreases expression | 1 |
| Tretinoin | decreases expression | 1 |
| Asbestos, Crocidolite | decreases expression | 1 |
| Cadmium Chloride | increases abundance, increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.